Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherRENAL PHARMACOLOGY

Probenecid Alters Topotecan Systemic and Renal Disposition by Inhibiting Renal Tubular Secretion

William C. Zamboni, Peter J. Houghton, Randall K. Johnson, Jeff L. Hulstein, William R. Crom, Pam J. Cheshire, Suzan K. Hanna, Lois B. Richmond, Xiaolong Luo and Clinton F. Stewart
Journal of Pharmacology and Experimental Therapeutics January 1998, 284 (1) 89-94;
William C. Zamboni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Houghton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall K. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeff L. Hulstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William R. Crom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pam J. Cheshire
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzan K. Hanna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lois B. Richmond
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaolong Luo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clinton F. Stewart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Topotecan is primarily eliminated by the kidneys, with 60 to 70% of the dose recovered as topotecan total in the urine. To elucidate the mechanisms of topotecan renal clearance, we evaluated the effect of probenecid on topotecan renal and systemic disposition in mice. Topotecan lactone or hydroxy acid (1.25 mg/kg i.v.) was administered alone or in combination with probenecid (600 or 1200 mg/kg) given by oral gavage 30 min before and 3 hr after topotecan. Serial blood samples (three mice per time point) and urine samples (five mice per treatment arm) were collected during a 6-hr period. Compared with topotecan alone, coadministration of topotecan lactone or hydroxy acid with probenecid (600 mg/kg) decreased topotecan lactone, total, and hydroxy acid systemic clearance, and total renal clearance. The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng·hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng·hr/ml alone, P < .05). By inhibiting renal tubular secretion, probenecid decreased renal and systemic clearance which led to an increase in topotecan systemic exposure. These data suggest that probenecid primarily inhibited secretion of the anionic hydroxy acid form, and by direct or indirect mechanisms increased topotecan lactone systemic exposure. Topotecan elimination through renal tubular secretion may have clinical relevance for the use of topotecan in patients with altered renal function.

Footnotes

  • Send reprint requests to: Clinton F. Stewart, Pharm.D., Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, 332 N. Lauderdale, Memphis, TN 38105.

  • ↵1 This work was supported in part by US Public Health Service award CA23099, Cancer Center Support grant CA21765 and by American, Lebanese, Syrian Associated Charities (ALSAC).

  • Abbreviations:
    AUC
    area under the plasma concentration time curve
    GFR
    glomerular filtration rate
    • Received April 11, 1997.
    • Accepted September 15, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 284, Issue 1
1 Jan 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Probenecid Alters Topotecan Systemic and Renal Disposition by Inhibiting Renal Tubular Secretion
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherRENAL PHARMACOLOGY

Probenecid Alters Topotecan Systemic and Renal Disposition by Inhibiting Renal Tubular Secretion

William C. Zamboni, Peter J. Houghton, Randall K. Johnson, Jeff L. Hulstein, William R. Crom, Pam J. Cheshire, Suzan K. Hanna, Lois B. Richmond, Xiaolong Luo and Clinton F. Stewart
Journal of Pharmacology and Experimental Therapeutics January 1, 1998, 284 (1) 89-94;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherRENAL PHARMACOLOGY

Probenecid Alters Topotecan Systemic and Renal Disposition by Inhibiting Renal Tubular Secretion

William C. Zamboni, Peter J. Houghton, Randall K. Johnson, Jeff L. Hulstein, William R. Crom, Pam J. Cheshire, Suzan K. Hanna, Lois B. Richmond, Xiaolong Luo and Clinton F. Stewart
Journal of Pharmacology and Experimental Therapeutics January 1, 1998, 284 (1) 89-94;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Regulation of Renin Secretion Through Reversible Phosphorylation of Myosin by Myosin Light Chain Kinase and Protein Phosphatase Type 1
  • Interaction of l-Arginine Analogs withl-Arginine Uptake in Rat Renal Brush Border Membrane Vesicles
  • Effects of Trimetazidine on Lipid Peroxidation and Phosphorus Metabolites during Cold Storage and Reperfusion of Isolated Perfused Rat Kidneys
Show more RENAL PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics